{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination broadens interferon signaling and antigen processing to sensitize tumors.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C02",
      "claim": "Combining the mRNA vaccine with anti-PD-L1 therapy improves tumor control in mice and mirrors better retrospective human outcomes.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "Human survival data come from a retrospective, non-randomized cohort subject to confounding and heterogeneity."
    },
    {
      "claim_id": "C03",
      "claim": "Prior SARS-CoV-2 mRNA vaccination was associated with improved survival among metastatic patients receiving ICI.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        },
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment.",
          "line_ref": "L30"
        }
      ],
      "caveat": "Retrospective design, variable vaccination timing, and patient heterogeneity limit causal interpretation of the human survival association."
    },
    {
      "claim_id": "C04",
      "claim": "Mechanistic probes including IFNAR1 blockade showed the sensitization benefit depends on type I interferon signaling.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).",
          "line_ref": "L16"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "Mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    }
  ]
}